# US 11,304,989 B2 · Peptides for use in the treatment of viral infections > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,304,989 B2 - Document ID: US11304989B2 - Status: Granted - Kind: B2 - Application number: 16/753,083 - Filed: 2018-10-02 - Published: 2020-09-03 - Granted: 2022-04-19 - Earliest claimed: 2017-10-06 - Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem - Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd - Inventors: Raymond Kaempfer; Gila Arad - Web page: https://patentgrep.com/patent/US11304989B2 ## CPC - A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} - A61P 31/12: Antivirals - A61K 31/7012: Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K31/191; ascorbic acid A61K31/375) - A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)} - A61P 31/16: for influenza or rhinoviruses - C07K 7/06: having 5 to 11 amino acids - A61K 31/215: of carboxylic acids - A61K 31/351: not condensed with another ring - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent. ## Claims ### Claim 1 A method for the treatment of an influenza Type A viral pathogen infection in a human subject in need of such treatment, said method comprising the step of administering to said subject a therapeutically effective amount of: (a) an isolated peptide selected from the group consisting of SPMLVAYD (SEQ ID NO: 2) and (D-Ala)-SPMLVAYD-(D-Ala) SEQ ID NO: 7, or pharmaceutically acceptable salts and esters thereof, and (b) at least one antiviral therapeutic agent that is a viral neuraminidase inhibitor, wherein the amount of at least one of (a) and (b) administered is sub-therapeutic. ### Claim 2 (depends on 1) The method of claim 1, wherein said treatment prevents worsening, arrests and/or ameliorates at least one symptom of said viral pathogen infection to said subject or an organ or tissue of said subject, associated with said viral pathogen infection, and/or wherein said symptom is at least one of fever, acute respiratory distress syndrome (ARDS), multiple organ dysfunction syndrome (MODS), systemic inflammatory response syndrome (SIRS), hypotension, tachycardia, dyspnea, ischemia, insufficient tissue perfusion, uncontrollable hemorrhage, multisystem organ failure or severe metabolism dysregulation. ### Claim 3 (depends on 1) The method according to claim 1, wherein said isolated peptide and said at least one antiviral therapeutic agent, are administered to said subject following exposure to said viral pathogen, before or after manifestation of clinical symptoms/damage in said subject. ### Claim 4 (depends on 1) The method of claim 1, wherein said at least one antiviral therapeutic agent is administered to said subject at a suboptimal dose. ### Claim 5 (depends on 1) The method of claim 1, wherein said isolated peptide is administered to said human subject at an amount of from about 0.05 mg to about 0.5 mg peptide/kg body weight of said subject. ### Claim 6 (depends on 1) The method of claim 1, wherein said isolated peptide and said at least one antiviral therapeutic agent are administered to said subject simultaneously, or wherein said isolated peptide and said at least one antiviral therapeutic agent are administered to said subject at different time points, at different intervals between administrations, for different treatment periods, and/or at any order of administration and/or wherein each one of said isolated peptide or composition comprising the same and said antiviral therapeutic agent is administered at one or more identical or different treatment periods of one or more weeks of once daily, once every three days, once every five days or once weekly administrations of each of said isolated peptide and said antiviral agent, wherein said treatment periods are consecutive or are set apart from each other by non-treatment intervals of 1 or several days or 1 or several weeks and or wherein each one of said isolated peptide or composition comprising the same and said antiviral agent is administered to said subject immediately following, or within from about 30 minutes up to about 10 days following exposure to the virus and/or wherein said interval between administration of said isolated peptide and said at least one antiviral therapeutic agent is between about 5 minutes to about 5 hours. ### Claim 7 (depends on 1) The method of claim 1, wherein said viral neuraminidase inhibitor is Oseltamivir or Zanamivir. ### Claim 8 (depends on 7) The method of claim 7, wherein said viral neuraminidase inhibitor is Oseltamivir.